A bitter pill! Gland Pharma records biggest fall since listing, hits 52-week low
Another domestic brokerage firm Nirmal Bang Institutional Equities has cut its revenue and EBITDA estimates for the next three fiscals due to near-term slowdown in growth, owing to cost inflation and volume decline in the US.
